Clinical trial · Observational
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced Melanoma - a Prospective, Multicentric HFV Research Project/Category A
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
TUPRO-Melanoma is the first project of the Tumour Profiler (TUPRO) research collaboration, which in the long-term aims to generate data that will help to understand and report the individual tumour biology and the clinical parameters for patients with advanced malignancies using innovative molecular technologies and computational analyses for in-depth molecular profiling. TUPRO-Melanoma is an exploratory project that aims to establish a comprehensive platform for in-depth tumour profiling in patients suffering from advanced melanoma. Aims of this platform are to establish logistics and algorithms for integrative analyses and discover new molecular biomarker profiles/patterns.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Establishment of an in-deepth tumor profiling platform | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (9)
- measure
- Sample Processing and Report Generation (Tumor Biopsy, peripheral blood sample and stool sample)
- timeFrame
- through study completion, an average of 1 year
- description
- * Number of samples (with sufficient material and quality) made available for intended analysis per technology * Number of molecular summary reports (generated from the translational domain) that could be made available to the Tumour Board * Number (proportion) of cases in which the Tumour Board considers the molecular summary report as useful for making a treatment recommendation on a scale from zero (not useful at all) to five (very useful). * Number (proportion) of cases in which the treating physician considers the Tumour Board's recommendation as useful for making a treatment decision on a scale from zero (not useful at all) to five (very useful) * Types of molecular information and combinations of molecular information from the biotechnology domain that the pre-Tumour Board considers as useful for making a treatment recommendation beyond routine diagnostics (incl. routine pathology and NGS testing)
- measure
- Classification of proposed treatment options (according to the one of the 7 categories below)
- timeFrame
- through study completion, an average of 1 year
- description
- Select one of the following categories: * On-label treatment with molecular matched treatment (SwissMedic label as reference) +/- radiotherapy or chemotherapy; * Treatment with classical chemotherapy +/- radiotherapy (on label if label available); * Referral to a suitable clinical trial; * Off-label treatment (SwissMedic label as reference) with molecular matched treatment or immunotherapy +/- radiotherapy or chemotherapy; * Off-label treatment (authorization in countries with comparable control systems for medicinal products as defined by SwissMedic) with molecular matched treatment or immunotherapy +/- radiotherapy or chemotherapy; * Immunotherapy * No active anti-tumour treatment (best supportive care)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * ECOG performance status ≤2 (not bedridden for more than 50% of waking hours) * Stage III or IV cutaneous melanoma, or rare melanoma subtypes at any stage that require systemic therapy * Written informed consent according to national legal and regulatory requirements prior to any project specific procedures Exclusion Criteria: * Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the sponsor-project leader or site project leader may interfere with the project or affect patient compliance * Legal incompetence
References
Publications (1)
- DERIVEDMiglino N, Toussaint NC, Ring A, Bonilla X, Tusup M, Gosztonyi B, Mehra T, Gut G, Jacob F, Chevrier S, Lehmann KV, Casanova R, Jacobs A, Sivapatham S, Boos L, Rahimzadeh P, Schuerch M, Sobottka B, Chicherova N, Yu S, Wegmann R, Mena J, Milani ES, Goetze S, Esposito C, Sarabia Del Castillo J, Frei AL, Nowak M, Irmisch A, Kuipers J, Baciu-Dragan MA, Ferreira PF, Singer F, Bertolini A, Prummer M, Lischetti U; Tumor Profiler Consortium; Aebersold R, Bacac M, Maass G, Moch H, Weller M, Theocharides APA, Manz MG, Beerenwinkel N, Beisel C, Pelkmans L, Snijder B, Wollscheid B, Heinzelmann V, Bodenmiller B, Levesque MP, Koelzer VH, Ratsch G, Dummer R, Wicki A. Feasibility of multiomics tumor profiling for guiding treatment of melanoma. Nat Med. 2025 Jul;31(7):2430-2441. doi: 10.1038/s41591-025-03715-6. Epub 2025 May 27. PMID 40425842